Palo Alto Investors LP Uro Gen Pharma Ltd. Transaction History
Palo Alto Investors LP
- $626 Million
- Q4 2024
A detailed history of Palo Alto Investors LP transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Palo Alto Investors LP holds 24,500 shares of URGN stock, worth $231,770. This represents 0.04% of its overall portfolio holdings.
Number of Shares
24,500
Previous 24,500
-0.0%
Holding current value
$231,770
Previous $311,000
16.4%
% of portfolio
0.04%
Previous 0.04%
Shares
1 transactions
Others Institutions Holding URGN
# of Institutions
137Shares Held
36.2MCall Options Held
57.7KPut Options Held
9.8K-
Rtw Investments, LP New York, NY3.83MShares$36.3 Million0.67% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.93MShares$27.7 Million0.06% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$21.8 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$20.8 Million0.0% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A61.75MShares$16.5 Million0.03% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $215M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...